BioVie 3Q 2026: EPS ($0.68) — 10-Q Summary

BioVie reported a wider quarterly loss of $5.61M, or $0.68 per share, due to increased R&D expenses and lower interest income. The company is pre-revenue. Key programs, including Parkinson's disease and Long COVID, showed positive results. The Phase 3 liver program protocol is being finalized. According to the company, R&D expenses rose primarily due to the Long COVID Phase 2 program.

Original reporting
Published Nov 6, 2026, 10:21 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 6, 2026, 10:32 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
BioVie 3Q 2026: EPS ($0.68) — 10-Q Summary — source image
Decision brief

The 30-second read

$BIVIBearishMed
01

Why it matters

The wider loss and R&D spend increase signal short‑term cash burn, but the trial readouts provide data points for future valuation.

02

Market read

The filing provides fresh earnings data and trial updates that can move the stock, making it a relevant short‑term trading catalyst.

03

What to watch

Potential future partnership or licensing deals for the Long COVID program could mitigate the current loss.

Relevance 7/10Novelty 7/10Timing: after-hours reaction

Background

BioVie is a pre‑revenue biotech focused on neuro‑degenerative and post‑viral conditions, trading on Nasdaq under BIVI.

Company-level read

Ticker impact

$BIVIBearishHigh confidence
Context

BioVie reported a wider quarterly loss and new Phase 2 trial results for its Long COVID and Parkinson's programs in its 10‑Q filing.

Expected impact

likely downward pressure as the market prices in the larger loss and modest trial outcomes

Evidence & confidence

Earnings miss and widened loss are fresh material; investors typically react negatively to higher expenses and lack of revenue.

Market effects

Highlights ongoing challenges for biotech firms developing Long COVID therapies, may temper enthusiasm for similar small‑cap pipelines.

Limited to US biotech sector; no broader regional effect.

Minimal global impact; primarily relevant to investors in US biotech microcaps.

Counterpoint

If the Phase 2 data shows statistically significant improvements in high‑symptom subgroups, the long‑term upside could outweigh the near‑term loss.

Key entities

  • BioVie Inc.

    Biotech firm reporting its Q3 2026 10‑Q results.

Related articles

$BIVIHighAI 8/10

BioVie to present additional Parkinson’s drug data at international conference

BioVie Inc (BIVI, BIVIW) will present additional data on its experimental Parkinson's drug, bezisterim, at the AD/PD 2027 conference in Barcelona. The data, from the Phase 2 SUNRISE-PD trial, showed significant improvements in motor and non-motor symptoms for patients with higher inflammation. The company reported a 1.23-point improvement in treated patients versus a 1.21-point worsening in the placebo group, with a p-value of 0.0006.

$BIVIMedAI 8/10

BioVie identifies two Long COVID patient groups with distinct responses to bezisterim

BioVie Inc. (BIVI, BIVIW) reported that its Long COVID trial identified two patient groups with distinct responses to its drug bezisterim. High-inflammatory patients showed cognitive improvements, while others improved in fatigue and post-exertional malaise. The trial, involving 203 participants, did not reach statistical significance overall. BioVie plans to present more data at an upcoming conference.